GET DAILY SIGNALSPasithea Therapeutics (KTTA) Q3 2026 Earnings Preview: Pipeline and Cash Runway in Focus
Key Takeaways
- Pasithea Therapeutics is expected to report its third-quarter 2026 results around November 12, 2026, after the market close.
- Wall Street consensus projects a net loss of approximately $0.21 per share for the quarter, versus a reported loss of $0.16 per share in the prior quarter.
- As a clinical-stage biotechnology company, Pasithea generates minimal revenue, so investors will focus on research and development spending, cash burn, and clinical updates rather than top-line growth.
- Key watch items include progress on PAS-004, its lead MEK inhibitor candidate, and PAS-003, its amyotrophic lateral sclerosis (ALS) program.
- The company's recent earnings history has been volatile, with a narrower-than-expected loss in Q1 2026 and a wider-than-expected loss in Q4 2025.
- For more information about the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
- Investors looking for automated market insights can also explore Trending AI Robots to see AI-driven trading strategies in action.
Why This Report Matters for a Clinical-Stage Biotech
Pasithea Therapeutics Corp. (KTTA) focuses on central nervous system disorders, RASopathies, and certain cancers. With no approved products on the market, its results hinge on operating expenses rather than sales. I view this upcoming release as a checkpoint on execution—how well capital is being allocated, whether cash reserves support ongoing work, and if clinical timelines remain on track. Earlier quarters have shown noticeable swings in the per-share loss, which is typical for development-stage companies where spending can shift with trial milestones. At the current share price level, any fresh details on the pipeline or funding position could influence sentiment noticeably.
Consensus Estimates and Recent History
Analysts anticipate a loss of about $0.21 per share for the third quarter ended September 30, 2026. Revenue is projected to stay minimal, around $0.2 million or below, in line with the company's pre-commercial stage. For comparison, the second quarter brought a $0.16 per share loss that matched estimates. The first quarter of 2026 came in better than expected at $0.12 per share versus a $0.45 forecast, while the fourth quarter of 2025 posted a wider loss of $0.89 per share. These variations highlight how one-time items and shifting research timelines can affect the bottom line in this sector. Beyond the headline number, attention will likely turn to research and development outlays, administrative costs, and the overall cash balance that signals how long operations can continue without new capital.
Sentiment and Potential Market Response
Investor views ahead of the report reflect the usual pressures on early-stage biotechs: ongoing cash use and event-driven risk around clinical data. Shares of KTTA have moved within a broad range over the past year, and prior reactions to earnings have varied. A result better than the -$0.21 consensus, especially if accompanied by notes on controlled spending, could support a more constructive tone. On the other hand, signs of faster cash depletion or an outsized loss might weigh on the stock given its modest market value. Any mention of financing plans would also draw scrutiny, as share dilution remains a recurring consideration for companies without product revenue.
Forward Signals Worth Tracking
After the release, several items stand out for follow-up. Commentary on the cash runway will be closely examined, since a shorter horizon could point to an eventual equity raise. Updates on PAS-004, the MEK inhibitor aimed at RASopathies and related tumors, and PAS-003 for ALS will carry more weight than the quarterly loss figure itself. Progress on trial enrollment, data readouts, or regulatory steps often serves as the real driver of valuation in this space. In addition, the trend in research spending should align with tangible milestones. Broader industry conditions, such as financing availability for small biotechs, may shape how the market interprets the results overall. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
AI Tools in My Research Workflow
When reviewing names like KTTA, I sometimes cross-reference sector peers with Tickeron's AI Screener. The tool lets me apply filters for market cap, volatility, and technical signals to surface comparable setups quickly. It has become a regular part of my process for organizing ideas across clinical-stage companies without adding significant time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KTTA in upward trend: 10-day moving average broke above 50-day moving average on November 11, 2026
The 10-day moving average for KTTA crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on KTTA as a result. In 75 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for KTTA just turned positive on November 03, 2026. Looking at past instances where KTTA's MACD turned positive, the stock continued to rise in 33 of 45 cases over the following month. The odds of a continued upward trend are 73%.
KTTA moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where KTTA advanced for three days, in 141 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for KTTA moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 15 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 33 cases where KTTA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KTTA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KTTA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. KTTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.388) is normal, around the industry mean (3.498). P/E Ratio (-0.429) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement